Crescent Capital III is a venture capital fund part funded by the European Regional Development Fund under the EU Investment for Growth and Jobs Programme 2014-2020 – Crescent Capital III
FIND OUT MORE

News from Crescent and our Investees


PathXL wins top Frost and Sullivan Image Analysis Award with TissueMark

Frost and Sullivan selects PathXL’s TissueMark as winner of the 2014 European New Product Innovation Award for Automated Image... Find Out More
Balcas delivers well ahead of schedule

Balcas delivers well ahead of schedule

THE Scotch whisky industry is used to taking it time to deliver the right result but Fermanagh based environmental... Find Out More

PathXL confirmed a winner in the Deloitte Fast 50 awards

The Fast 50 awards have been operating in Ireland for the last fourteen years providing recognition for top performing... Find Out More
New technology will accelerate cancer diagnostics and drug development

New technology will accelerate cancer diagnostics and drug development

TissueMark software automatically marks and detects potentially cancerous sections in tissue samples with unprecedented levels of speed and accuracy... Find Out More

Belfast-based camera firm Andor Technology buys second company in two weeks

Belfast-based camera firm Andor Technology buys second company in two weeks Andor Technology follows £6.8m Toronto deal with California coup... Find Out More
‘Dolly the Sheep’ Business Mastermind Joins Digital Pathology Company

‘Dolly the Sheep’ Business Mastermind Joins Digital Pathology Company

PathXL welcomes one of UK’s leading medtech minds onto their Board One of the leading names in the UK’s... Find Out More